Although this represents a major step forward for patients with HES, withdrawal of therapeutic agent(s) active on T-cells is a subject of concern for patients with L-HES because of the pre-malignant potential of CD3-CD4+ T-cells. The gene discussed is CD4; the disease is hypereosinophilic syndrome.